Companion Animal Arthritis Market Report 2026

The companion animal arthritis market size has grown rapidly in recent years. It will grow from $4.07 billion in 2025 to $4.48 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to growth in companion animal ownership, increasing lifespan of dogs and cats, rising awareness of pet joint health, expansion of veterinary care infrastructure, availability of anti-inflammatory medications.

The companion animal arthritis market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to rising pet humanization trends, increasing demand for advanced arthritis therapies, growth in senior pet population, expansion of online veterinary pharmacies, innovation in combination therapies and supplements. Major trends in the forecast period include rising prevalence of age-related arthritis in pets, increasing pet owner spending on chronic care, growing adoption of nutraceuticals and joint supplements, shift toward early diagnosis and preventive treatment, rising demand for long-term pain management solutions.

The increasing trend of pet adoption is expected to drive the growth of the companion animal arthritis market going forward. Pet adoption refers to the process of assuming responsibility for a pet from a shelter or previous owner and providing care, nutrition, and a safe living environment. Pet adoption is rising due to greater emotional awareness, as more individuals seek companionship and improved mental well-being through caring for animals. Companion animal arthritis treatments support pet adoption by assuring prospective owners that age-related joint conditions can be effectively managed, making older pets easier to care for and more adoptable. For example, in 2024, according to Shelter Animals Count (SAC), a US-based nonprofit organization, dog adoption rates, measured as the percentage of adoptions relative to intakes, increased from 56% in 2023 to 57% in 2024. Therefore, the rising trend of pet adoption is contributing significantly to the growth of the companion animal arthritis market.

Leading companies operating in the companion animal arthritis market are increasingly emphasizing technological innovations, including advanced therapeutic products and supplements, to deliver effective pain management and improved joint health, thereby enhancing the quality of life for aging and arthritis-affected pets. Bonqat is a newly developed medication for cats that helps alleviate anxiety during stressful situations such as transportation or veterinary visits without causing sedation. The product is designed to calm cats, making travel and clinical visits easier for both pets and their owners. For instance, in April 2024, Zoetis Inc., a US-based manufacturer of medicines and vaccines for pets and livestock, introduced Bonqat (pregabalin oral solution) for the relief of acute feline anxiety and fear associated with transportation and veterinary visits, which can otherwise hinder routine care. The oral solution can be administered directly or mixed with food, offering convenience for pet owners. The dosage is minimal (0.1 mL/kg), and a majority of cat owners have reported that administration is easy.

In January 2024, Ceva Santé Animale S.A., a France-based provider of animal health solutions encompassing preventive vaccines, pharmaceutical products for farm and companion animals, animal welfare products, and related equipment and services, acquired Scout Bio Inc. for an undisclosed amount. Through this acquisition, Ceva aims to accelerate its global biotechnology initiatives and expand its biotherapeutic capabilities by incorporating Scout Bio’s pipeline of monoclonal antibodies and gene therapy innovations to address chronic conditions in pets, thereby strengthening its position in advanced pet therapeutics. Scout Bio Inc. is a US-based biotechnology company focused on developing novel biotherapeutic products for pets, including one-time gene therapies and monoclonal antibody treatments designed to enable long-term therapeutic protein expression for chronic animal health conditions.

Major companies operating in the companion animal arthritis market are Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Bayer Animal Health, Vetoquinol, Ceva Santé Animale, Dechra Pharmaceuticals, PetMed Express, Pet Health Solutions, VetriScience, Canine Arthritis Management, Integrative Pet Care, The Honest Kitchen, Vetri-Science Laboratories, Anivive Lifesciences, Nutramax Laboratories, Hill's Pet Nutrition, Royal Canin, Medivet, Virbac, Canna-Pet, Lintbells, Allivet, Petlab Co.

North America was the largest region in the companion animal arthritis market in 2025. The regions covered in the companion animal arthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the companion animal arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the companion animal arthritis market by increasing the cost of imported active pharmaceutical ingredients, supplements, and veterinary medical products, leading to higher treatment costs. The impact is most evident in medication and supplement segments and in regions reliant on imports such as Asia-Pacific and parts of Europe. However, tariffs have encouraged local manufacturing, regional sourcing of supplements, and increased investment in domestic veterinary pharmaceutical production, supporting long-term supply chain resilience.

The companion animal arthritis market research report is one of a series of new reports that provides companion animal arthritis market statistics, including companion animal arthritis industry global market size, regional shares, competitors with a companion animal arthritis market share, detailed companion animal arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the companion animal arthritis industry. This companion animal arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion animal arthritis refers to a condition involving inflammation of one or more joints in companion animals such as cats, dogs, and other exotic animals. Companion animal arthritis develops in the bones when the cartilage between joints becomes rougher and more worn, forcing the bone surfaces to rub against one another.

The main type of companion animal arthritis are dogs, cats, and others types. The dogs companion animal arthritis are used for controlling pain and inflammation in dogs. Dogs are domesticated canines (Canis familiaris) that are usually kept as pets or trained for hunting, guarding individuals or property. The companion animal arthritis indication are osteoarthritis and, other arthritis, that are treatment through medication, supplements and other treatment, which are sold and distributed through veterinary hospitals and clinics, retail pharmacies, online stores, and others.

The companion animal arthritis market includes revenues earned by entities by NSAIDs, monoclonal antibiotics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.